BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 32881214)

  • 21. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
    Ye ZW; Jin DY
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Status of Famotidine in COVID-19 Patients: A Review.
    Mohseni M; Raissi V; Sharifan Y; Barikro K; Amiri S; Mohseni MS; Raeisi F; Masoumi K; Khodakarami S; Raiesi O
    Infect Disord Drug Targets; 2022; 22(3):e070122200096. PubMed ID: 34994318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 in Children: Clinical Approach and Management.
    Sankar J; Dhochak N; Kabra SK; Lodha R
    Indian J Pediatr; 2020 Jun; 87(6):433-442. PubMed ID: 32338347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.
    Edler C; Schröder AS; Aepfelbacher M; Fitzek A; Heinemann A; Heinrich F; Klein A; Langenwalder F; Lütgehetmann M; Meißner K; Püschel K; Schädler J; Steurer S; Mushumba H; Sperhake JP
    Int J Legal Med; 2020 Jul; 134(4):1275-1284. PubMed ID: 32500199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
    Yaqinuddin A; Kashir J
    Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation.
    Suess C; Hausmann R
    Int J Legal Med; 2020 Jul; 134(4):1285-1290. PubMed ID: 32504146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods.
    Marofi F; Azizi R; Motavalli R; Vahedi G; Nasimi M; Yousefi M; Motavalli Y; Tahmasebi S; Gharibi T; Mohammed RN; Etemadi J; Khiavi FM
    Anticancer Agents Med Chem; 2021 Oct; 21(16):2142-2162. PubMed ID: 33563186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.
    Sansone NMS; Boschiero MN; Ortega MM; Ribeiro IA; Peixoto AO; Mendes RT; Marson FAL
    Lancet Reg Health Am; 2022 Apr; 8():100177. PubMed ID: 35018359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19.
    Li C; Zhao H; Cheng L; Wang B
    Drug Des Devel Ther; 2021; 15():1345-1356. PubMed ID: 33824579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
    Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.
    Ferrara F; Vitiello A
    Wien Klin Wochenschr; 2021 Sep; 133(17-18):958-965. PubMed ID: 33779831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Epidemiological Features of SARS-CoV-2 Patients in SARI Ward of a Tertiary Care Centre in New Delhi.
    Aggarwal A; Shrivastava A; Kumar A; Ali A
    J Assoc Physicians India; 2020 Jul; 68(7):19-26. PubMed ID: 32602676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
    Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
    FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.